Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRME Prime Medicine, Inc.

Post-Market Trading 11-07 19:48:18 EST

4.10

+0.00

0.00%

盘后4.14

+0.04+0.98%

19:04 EST

High4.24	Low4.06	Vol712.11K
Open4.10	D1 Closing4.10	Amplitude4.39%
Mkt Cap492.13M	Tradable Cap237.42M	Total Shares120.03M
T/O2.93M	T/O Rate1.23%	Tradable Shares57.91M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PRME","market":"US","secType":"STK","nameCN":"Prime Medicine, Inc.","latestPrice":4.1,"timestamp":1731013200000,"preClose":4.1,"halted":0,"volume":712108,"hourTrading":{"tag":"盘后","latestPrice":4.14,"preClose":4.1,"latestTime":"19:04 EST","volume":9576,"amount":39284.132328,"timestamp":1731024278850},"delay":0,"floatShares":57906899,"shares":120030813,"eps":-2.131794,"marketStatus":"Post-Market Trading","change":0,"latestTime":"11-07 19:48:18 EST","open":4.1,"high":4.24,"low":4.06,"amount":2929873.655636,"amplitude":0.043902,"askPrice":4.4,"askSize":3500,"bidPrice":4.1,"bidSize":39,"shortable":3,"etf":0,"ttmEps":-2.131794,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1731027600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1666238400000,"exchange":"NASDAQ","adjPreClose":4.1,"preHourTrading":{"tag":"盘前","latestPrice":4.21,"preClose":4.1,"latestTime":"08:30 EST","volume":2000,"amount":8360.0006,"timestamp":1730986205800},"postHourTrading":{"tag":"盘后","latestPrice":4.14,"preClose":4.1,"latestTime":"19:04 EST","volume":9576,"amount":39284.132328,"timestamp":1731024278850},"volumeRatio":0.963047,"impliedVol":1.8375,"impliedVolPercentile":0.8294},"requestUrl":"/m/hq/s/PRME/tweets","defaultTab":"tweets","newsList":[{"id":"2478971963","title":"Prime Medicine treatment of retinal dystrophy granted orphan designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2478971963","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478971963?lang=en_us&edition=fundamental","pubTime":"2024-10-26 03:10","pubTimestamp":1729883411,"startTime":"0","endTime":"0","summary":"Prime Medicine’s (PRME) treatment of retinal dystrophy due to USH2A gene mutations was granted FDA orphan designation, according to a post to the a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/prime-medicine-treatment-of-retinal-dystrophy-granted-orphan-designation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/prime-medicine-treatment-of-retinal-dystrophy-granted-orphan-designation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PRME"],"gpt_icon":0},{"id":"2478607308","title":"Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2478607308","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478607308?lang=en_us&edition=fundamental","pubTime":"2024-10-25 18:38","pubTimestamp":1729852680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 25, 2024 06:38 ET (10:38 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME"],"gpt_icon":0},{"id":"2477797687","title":"Prime Medicine presents data from multiple studies showcasing LNP platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2477797687","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477797687?lang=en_us&edition=fundamental","pubTime":"2024-10-24 20:20","pubTimestamp":1729772417,"startTime":"0","endTime":"0","summary":"Prime Medicine (PRME) presented data from multiple studies showcasing the potential of its proprietary, universal lipid nanoparticle, LNP, platform...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/prime-medicine-presents-data-from-multiple-studies-showcasing-lnp-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/prime-medicine-presents-data-from-multiple-studies-showcasing-lnp-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"2477198682","title":"Prime Medicine- on Track to Initiate Ind-Enabling Activities for Wilson's Disease Program in 4Q 2024, With Ind and/or Cta Filing Expected in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2477198682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477198682?lang=en_us&edition=fundamental","pubTime":"2024-10-24 20:06","pubTimestamp":1729771594,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241024:nFWN3M00WR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"gpt_icon":0},{"id":"2475650945","title":"Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2475650945","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475650945?lang=en_us&edition=fundamental","pubTime":"2024-10-15 20:00","pubTimestamp":1728993600,"startTime":"0","endTime":"0","summary":"--  On-track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 --. CAMBRIDGE, Mass., Oct. 15, 2024  -- Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the Company will highlight advances from across its Prime Editing pipeline and platform at the upcoming European Society of Gene and Cell Therapy  31st Annual Congress, being held October 22-25, 2024 in Rome, and the American Association for the Study of Liver Diseases , being held November 15-19, 2024 in San Diego.Poster Title: Methods for genome-wide detection of single strand breaks induced by gene editors reveals the specificity of SpCas9 nuclease domains and provides comprehensive lists of potential off-targets for Prime EditorsDate & Time: October 24, 2024, 2:00 – 2:30 p.m. CEST. Poster Title: Prime Editing advancements enable in vivo therapeutic correction o","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oPDNSXBzIFbD2e.XWB7MDA--~B/aD0zNzUwO3c9MTEyNDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/300f275153cd1bd628bbd71855c8c15c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oPDNSXBzIFbD2e.XWB7MDA--~B/aD0zNzUwO3c9MTEyNDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/300f275153cd1bd628bbd71855c8c15c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/prime-medicine-highlight-preclinical-data-120000335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PRME"],"gpt_icon":1},{"id":"2472032548","title":"Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2472032548","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472032548?lang=en_us&edition=fundamental","pubTime":"2024-10-02 18:29","pubTimestamp":1727864940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 02, 2024 06:29 ET (10:29 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME"],"gpt_icon":0},{"id":"2472587878","title":"PRME Stock Rises 11.8% on Collaboration With Bristol Myers","url":"https://stock-news.laohu8.com/highlight/detail?id=2472587878","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472587878?lang=en_us&edition=fundamental","pubTime":"2024-10-02 02:44","pubTimestamp":1727808240,"startTime":"0","endTime":"0","summary":"Shares of Prime Medicine, Inc. PRME were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb BMY.The collaboration is aimed at developing reagents for the next generation of ex vivo T-cell therapies.Year to date, PRME’s shares have lost 56.3% compared with the industry’s decline of 1.2%.Prime Medicine is deploying its proprietary gene editing technology, Prime Editing platform, to develop a new class of differentiated one-time curative genetic therapies.Per the terms of the deal, Bristol Myers will be responsible for the development, manufacturing and commercialization of the next-generation cell therapies, with support from Prime Medicine in gene editing strategy and reagent development.In exchange, PRME will receive an upfront payment of $55 million and an equity investment worth $55 million from BMY.Prime Medicine is also eligible to receive more than $3.5 billion in milestones, including up to $1.4 b","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/prme-stock-rises-11-8-184400789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1074936037.SGD","LU1093756168.USD","BK4585","LU0321505868.SGD","BK4588","IE00BJJMRZ35.SGD","BMY","IE0009355771.USD","LU0225284248.USD","LU1032466523.USD","LU1670710588.SGD","LU2242652126.USD","IE00B2B36J28.USD","BK4559","PRME","BK4534","FULC","BK4007","LU0114720955.EUR","LU0237698245.USD","LU0225771236.USD","LU0868494617.USD","LU0061475181.USD","BK4139","LU2133065610.SGD","LU2125154935.USD","LU0882574055.USD","KRYS","BK4581","LU1989771016.USD","LU0321505439.SGD","LU0985481810.HKD","LU1261432733.SGD","LU1670711040.USD","IE00BFTCPJ56.SGD","MYE","LU1670711123.USD","IE00BJT1NW94.SGD","LU0306806265.USD","LU0456855351.SGD","BK4532","LU1585245621.USD","LU1718418525.SGD","LU1291159041.SGD","BK4126","LU1571399168.USD","LU1670710661.SGD","LU2125154778.USD","LU0306807586.USD","LU1430594728.SGD"],"gpt_icon":1},{"id":"2472359373","title":"Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2472359373","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472359373?lang=en_us&edition=fundamental","pubTime":"2024-10-01 00:24","pubTimestamp":1727713472,"startTime":"0","endTime":"0","summary":"Prime Medicine  shares rallied 15% Monday after the company announced a collaboration with Bristol Myers Squibb , which includes a $55M equity investment. Under the deal, Prime  will receive $55M upfront and the $55M investment. Prime  will also be eligible to receive more than $3.5B in various milestone payments, along with royalties on any net sales. The collaboration will focus on the development and commercialization of several Prime Edited ex vivo T-cell therapies. Bristol Myers  will oversee development, manufacturing and commercialization of the cell therapies, with Prime  supporting the collaboration’s gene editing strategy and reagent development, Prime  said in a statement.  Prime  added that the Bristol Myers  deal will help extend its cash runway into the first half of 2026. Prime  also said it plans to report initial data in 2025 from a Phase 1/2 study of its therapy candidate for chronic granulomatous disease, along with new preclinical data in Q4 for its Wilson’s disease","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1617236488/image_1617236488.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1617236488/image_1617236488.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4154603-prime-medicine-stock-rallies-on-bristol-myers-deal-drug-updates","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU0306806265.USD","IE00BFTCPJ56.SGD","BK4532","LU0114720955.EUR","LU1032466523.USD","LU1261432733.SGD","LU2133065610.SGD","LU1670710661.SGD","LU2242646821.SGD","LU1093756325.SGD","LU2125154935.USD","BK4581","PRME","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU1074936037.SGD","LU0225284248.USD","LU1571399168.USD","BMY","IE0002141913.USD","IE00BSNM7G36.USD","LU0225771236.USD","LU1093756168.USD","BK4588","LU0237698245.USD","LU1718418525.SGD","BK4559","BK4585","LU1430594728.SGD","LU0306807586.USD","BK4534","LU1291159041.SGD","LU0882574055.USD","LU0321505868.SGD","LU2242652126.USD","LU2125154778.USD","LU1670711040.USD","LU0061475181.USD","IE00BJT1NW94.SGD","LU0456855351.SGD","BK4139","LU1585245621.USD","LU1670710588.SGD","BK4007","LU1670711123.USD","LU1989771016.USD","LU0321505439.SGD","LU0985481810.HKD","LU0868494617.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2472950335","title":"Bristol, Prime Medicine in deal to develop T-cell therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2472950335","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472950335?lang=en_us&edition=fundamental","pubTime":"2024-09-30 23:55","pubTimestamp":1727711748,"startTime":"0","endTime":"0","summary":"Prime Medicine  and Bristol Myers Squibb  will work together on the development of next-generation ex vivo T-cell therapies. The deal calls for Prime Medicine to design optimized Prime Editor reagents for several targets. Bristol Myers Squibb will handle development, manufacturing and commercialization of the T-cell therapies. Prime Medicine will provide support for gene editing strategy and reagent development. Terms of the agreement call for Prime Medicine to receive from Bristol a $55M upfront payment as well as a $55M equity investment. In addition, Prime Medicine is eligible for at least $3.5B in milestone payments: Up to $1.4B in development milestones and more than $2.1M in commercialization milestones, as well as sales royalties. In 2021, Bristol inked an agreement with Molecular Templates  potentially worth more than $1.3B to develop novel therapies for oncology targets.  In April, Bristol signed a $380M deal with contract manufacturer Cellares to produce CAR-T cell therapies.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1945894581/image_1945894581.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1945894581/image_1945894581.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4154520-bristol-prime-medicine-deal-develop-t-cell-therapies","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4007","LU1032466523.USD","IE00BSNM7G36.USD","BK4559","BK4581","IE0009355771.USD","LU1074936037.SGD","LU0114720955.EUR","LU0456855351.SGD","LU1718418525.SGD","BK4585","LU0225284248.USD","LU0225771236.USD","BK4534","LU1093756325.SGD","LU1670710588.SGD","IE00BFTCPJ56.SGD","LU2125154778.USD","BK4139","IE00B2B36J28.USD","LU0882574055.USD","LU1261432733.SGD","LU2133065610.SGD","LU1093756168.USD","IE0002141913.USD","LU0321505439.SGD","BK4588","LU0985481810.HKD","LU1571399168.USD","LU1670710661.SGD","LU2242646821.SGD","LU0868494617.USD","LU1670711123.USD","LU2242652126.USD","LU1670711040.USD","LU1291159041.SGD","LU1430594728.SGD","BK4532","LU0306806265.USD","LU0321505868.SGD","LU0237698245.USD","LU1989771016.USD","IE00BJJMRZ35.SGD","LU2125154935.USD","IE00BJT1NW94.SGD","PRME","BMY","LU0061475181.USD","LU0306807586.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2471857973","title":"Prime Medicine prioritization, Bristol deal positive, says Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2471857973","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471857973?lang=en_us&edition=fundamental","pubTime":"2024-09-30 21:45","pubTimestamp":1727703938,"startTime":"0","endTime":"0","summary":"Morgan Stanley notes that Prime Medicine (PRME) announced a prioritization of the company’s pipeline to focus on high-value programs and also annou...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/prime-medicine-prioritization-bristol-deal-positive-says-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/prime-medicine-prioritization-bristol-deal-positive-says-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1720051017.SGD","LU1074936037.SGD","LU0098860793.USD","BK4585","LU1668664300.SGD","LU2357305700.SGD","LU0320765646.SGD","LU1989772840.SGD","LU0314104364.USD","LU0267386448.USD","LU0225283273.USD","LU1363072403.SGD","PRME","LU1162221912.USD","LU0971096721.USD","BK4588","BK4534","BK4127","LU0106831901.USD","LU1548497426.USD","LU1989772923.USD","IE00BZ1G4Q59.USD","BK4504","BK4581","BK4139","LU1720051108.HKD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2471852383","title":"Prime Medicine, Inc. (PRME) Gets a Hold from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2471852383","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471852383?lang=en_us&edition=fundamental","pubTime":"2024-09-30 21:45","pubTimestamp":1727703933,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Dae Gon Ha maintained a Hold rating on Prime Medicine, Inc. (PRME – Research Report) today. The company’s shares opened tod...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/prime-medicine-inc-prme-gets-a-hold-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/prime-medicine-inc-prme-gets-a-hold-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4127","PRME","SF"],"gpt_icon":0},{"id":"2471633383","title":"Prime Medicine Shares up 29.8% on License Agreement With Bristol Myers Squibb for T-Cell Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2471633383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471633383?lang=en_us&edition=fundamental","pubTime":"2024-09-30 21:36","pubTimestamp":1727703418,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nL4N3LC14P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"gpt_icon":0},{"id":"2471807288","title":"Traders Consolidate Positions in Final Session for Q3, Driving Cautious Losses for US Equity Futures","url":"https://stock-news.laohu8.com/highlight/detail?id=2471807288","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471807288?lang=en_us&edition=fundamental","pubTime":"2024-09-30 20:59","pubTimestamp":1727701146,"startTime":"0","endTime":"0","summary":"US equity futures posted narrow losses ahead of Monday's opening bell as Wall Street is set to kick off the final trading session of September.The Dow Jones Industrial Average futures fell 0.1%, S&P 500 futures lost 0.2% and Nasdaq futures were down 0.3%.Oil prices were higher, with front-month global benchmarks North Sea Brent crude up 0.4% at $71.80 per barrel and US West Texas Intermediate crude up 0.3% at $68.41 per barrel.The Chicago Purchasing Managers' Index, due at 9:45 am ET, is seen coming in unchanged from August at 46.1 in September, according to estimates compiled by Bloomberg.In other world markets, Japan's Nikkei closed 4.8% lower, Hong Kong's Hang Seng ended 2.4% higher, and China's Shanghai Composite finished 8.1% higher. Meanwhile, UK's FTSE 100 declined 0.6%, and Germany's DAX index fell 0.8% in Europe's early afternoon session.In equities, Prime Medicine  shares rose 18% after the company said it entered into a strategic collaboration with Bristol-Myers Squibb  to d","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IE00B2B36J28.USD","BK4007","LU1291159041.SGD","LU1718418525.SGD","SDOW","LU1430594728.SGD","BK4559","LU0306806265.USD","PRME","LU2125154935.USD","IE00BFTCPJ56.SGD","LU1064927863.SGD","DJX","LU0321505439.SGD","BK4215","LU0456855351.SGD","LU1989771016.USD","LU0237698245.USD","LU0985481810.HKD","BK4581","EQR",".SPX","IE00BJT1NW94.SGD","LU0225284248.USD","LU1074936037.SGD","LU1093756168.USD","BMY","LU1261432733.SGD","LU2360032135.SGD","IE00BJJMRZ35.SGD","UDOW","LU0061475181.USD","STLA","LU2242646821.SGD","DOG",".DJI","LU1670711123.USD","LU2242652126.USD","BK4099","IE0009355771.USD","DXD","LU1032466523.USD","DDM","LU1585245621.USD","IE00BSNM7G36.USD","LU1093756325.SGD","BK4532","IE0002141913.USD","BK4585"],"gpt_icon":0},{"id":"2471080760","title":"Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb","url":"https://stock-news.laohu8.com/highlight/detail?id=2471080760","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471080760?lang=en_us&edition=fundamental","pubTime":"2024-09-30 20:51","pubTimestamp":1727700660,"startTime":"0","endTime":"0","summary":"Prime Medicine shares rose on Monday after the company signed a research collaboration and license agreement Bristol Myers Squibb to develop reagents for T-cell therapies.In premarket trading, shares were up 20% to $4.15. However, the stock is down more than 60% on a year-to-date basis through Friday's close.The biotechnology company said it will develop optimized reagents for the next generation of ex vivo T-cell therapies, while Bristol Myers Squibb will be responsible for development, manufacturing and commercialization of the cell therapies.Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, including up to $1.4 billion in development milestones and more than $2.1 billion in commercialization milestones, along with royalties on net sales.The company added that it expects its cash runway to fund operations into the first half of 2026, and th","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4126","LU1261432733.SGD","LU0868494617.USD","LU1571399168.USD","LU1074936037.SGD","LU0985481810.HKD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU1430594728.SGD","IE0009355771.USD","LU0306806265.USD","LU1585245621.USD","PRME","LU0882574055.USD","LU2133065610.SGD","LU1718418525.SGD","BK4585","LU2125154778.USD","BK4532","IE00BFTCPJ56.SGD","LU1989771016.USD","LU1670710588.SGD","BK4559","LU1291159041.SGD","BK4534","LU0321505439.SGD","LU0237698245.USD","LU1032466523.USD","LU2242652126.USD","LU2242646821.SGD","BK4007","LU1670711040.USD","LU0114720955.EUR","LU1670711123.USD","LU0061475181.USD","LU0225284248.USD","LU0306807586.USD","LU0456855351.SGD","LU1093756168.USD","LU1670710661.SGD","IE00BJT1NW94.SGD","MYE","LU2125154935.USD","BK4588","BMY","LU0321505868.SGD","BK4139","LU2360032135.SGD","BK4581","LU0225771236.USD"],"gpt_icon":0},{"id":"2471807565","title":"Sector Update: Health Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2471807565","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471807565?lang=en_us&edition=fundamental","pubTime":"2024-09-30 20:49","pubTimestamp":1727700555,"startTime":"0","endTime":"0","summary":"Health care stocks were flat to slightly lower premarket Monday as the Health Care Select Sector SPDR Fund  was down 0.01% and the iShares Biotechnology ETF  was flat recently.Prime Medicine  shares rose nearly 19% after the company announced a strategic research collaboration and license agreement with Bristol Myers Squibb  to develop reagents for the next generation of ex vivo T-cell therapies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2125154935.USD","LU1093756325.SGD","LU2125154778.USD","LU2242646821.SGD","LU0237698245.USD","LU0061475181.USD","BK4007","LU1291159041.SGD","LU1670711040.USD","LU0321505868.SGD","LU2242652126.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IBB","LU0985481810.HKD","LU0225284248.USD","LU0306807586.USD","LU1670710588.SGD","BK4581","LU1670710661.SGD","IE00BSNM7G36.USD","BK4585","LU1093756168.USD","BK4534","LU2133065610.SGD","LU0114720955.EUR","LU1989771016.USD","LU0321505439.SGD","BMY","PRME","IE0009355771.USD","LU0868494617.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU1074936037.SGD","LU0306806265.USD","LU1261432733.SGD","LU0456855351.SGD","LU1430594728.SGD","LU1670711123.USD","LU0225771236.USD","LU1585245621.USD","XLV","BK4588","LU1032466523.USD","BK4559","BK4139","LU1571399168.USD","LU0882574055.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2471809998","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2471809998","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471809998?lang=en_us&edition=fundamental","pubTime":"2024-09-30 19:51","pubTimestamp":1727697090,"startTime":"0","endTime":"0","summary":"Zhongchao  shares surged 87% pre-bell Monday following a muted session.TTEC Holdings  shares were up 35% after the company said it received an unsolicited takeover proposal from its chief executive officer.OneConnect  shares increased 17%, extending Friday's rally.Reliance Global  shares advanced 20% after Friday's 2.2% loss.Prime Medicine  shares rose 21% after the company said it entered into a strategic collaboration with Bristol-Myers Squibb  to develop reagents for T-cell therapies.Price: 2.4900, Change: +1.17, Percent Change: +88.64","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0985481810.HKD","LU0225771236.USD","LU0306806265.USD","BK4023","LU0237698245.USD","LU1585245621.USD","BK4559","LU2125154935.USD","BK4204","LU1571399168.USD","LU1670710661.SGD","LU2242652126.USD","LU1032466523.USD","LU2125154778.USD","BK4581","LU1718418525.SGD","IE00BSNM7G36.USD","LU1670710588.SGD","LU0225284248.USD","BK4106","LU1093756325.SGD","BK4531","LU2133065610.SGD","LU0114720955.EUR","LU0321505868.SGD","LU1291159041.SGD","BK4007","ZCMD","PRME","LU1074936037.SGD","LU1093756168.USD","TTEC","IE00BJJMRZ35.SGD","BK4532","IE0002141913.USD","OCFT","LU1430594728.SGD","LU2242646821.SGD","BMY","IE0009355771.USD","BK4226","BK4588","LU0321505439.SGD","RELI","LU1670711040.USD","LU1670711123.USD","IE00B2B36J28.USD","LU0456855351.SGD","LU0882574055.USD","LU2360032135.SGD"],"gpt_icon":0},{"id":"2471809885","title":"Prime Medicine Enters Research Collaboration, License Agreement With Bristol Myers Squibb","url":"https://stock-news.laohu8.com/highlight/detail?id=2471809885","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471809885?lang=en_us&edition=fundamental","pubTime":"2024-09-30 19:43","pubTimestamp":1727696607,"startTime":"0","endTime":"0","summary":"Prime Medicine  said Monday that it has entered into a strategic research collaboration and license agreement with Bristol Myers Squibb  to develop reagents for the next generation of ex vivo T-cell therapies.The company said it will receive a $55 million upfront payment and a $55 million equity investment from Bristol Myers Squibb, and will also be eligible to receive over $3.5 billion in milestones.Prime Medicine will design optimized Prime Editor reagents for a select number of targets, while Bristol Myers Squibb will be responsible for the development, manufacturing, and commercialization of the next-generation cell therapies, the company said.Prime Medicine's share price jumped almost 14% in recent Monday premarket activity.Price: 3.94, Change: +0.48, Percent Change: +13.87","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","IE00BSNM7G36.USD","LU0061475181.USD","LU1571399168.USD","LU1032466523.USD","LU0306806265.USD","LU1989771016.USD","BK4126","BK4532","LU1074936037.SGD","BK4139","LU0306807586.USD","LU1718418525.SGD","IE0002141913.USD","BK4588","LU2360032135.SGD","LU1093756325.SGD","LU0225771236.USD","IE00BFTCPJ56.SGD","LU2242646821.SGD","LU0225284248.USD","BK4585","LU0882574055.USD","BK4559","LU1430594728.SGD","LU0868494617.USD","LU1670710661.SGD","BK4581","LU2242652126.USD","LU1261432733.SGD","MYE","LU2133065610.SGD","LU0321505868.SGD","LU0114720955.EUR","IE0009355771.USD","IE00B2B36J28.USD","LU1093756168.USD","LU1291159041.SGD","LU0456855351.SGD","LU1585245621.USD","LU1670711040.USD","PRME","LU1670710588.SGD","LU2125154778.USD","BK4534","LU0321505439.SGD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU1670711123.USD","BMY"],"gpt_icon":0},{"id":"2471051248","title":"Prime Medicine Shares up 15% Premarket on License Agreement With Bristol Myers Squibb for T-Cell Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2471051248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471051248?lang=en_us&edition=fundamental","pubTime":"2024-09-30 19:23","pubTimestamp":1727695429,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nFWN3LC18I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1585245621.USD","LU2242646821.SGD","BK4534","LU0321505439.SGD","LU1670710588.SGD","IE0002141913.USD","BK4581","LU1291159041.SGD","LU0237698245.USD","BK4139","LU1261432733.SGD","LU0321505868.SGD","LU2133065610.SGD","LU2125154935.USD","LU1032466523.USD","IE00BJJMRZ35.SGD","LU1093756325.SGD","IE00B2B36J28.USD","LU1571399168.USD","LU1670711040.USD","PRME","LU1093756168.USD","IE0009355771.USD","LU2242652126.USD","LU0985481810.HKD","IE00BJT1NW94.SGD","LU0061475181.USD","BMY","LU1670711123.USD","LU0225284248.USD","LU0306807586.USD","LU0456855351.SGD","LU1989771016.USD","LU0306806265.USD","LU1074936037.SGD","IE00BFTCPJ56.SGD","BK4007","IE00BSNM7G36.USD","LU1670710661.SGD","BK4585","LU0882574055.USD","LU0114720955.EUR","BK4559","LU1430594728.SGD","LU0225771236.USD","LU2360032135.SGD","LU2125154778.USD","BK4532","LU0868494617.USD","LU1718418525.SGD"],"gpt_icon":0},{"id":"2471059998","title":"Prime Medicine unveils strategically focused pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2471059998","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471059998?lang=en_us&edition=fundamental","pubTime":"2024-09-30 19:15","pubTimestamp":1727694959,"startTime":"0","endTime":"0","summary":"Prime Medicine (PRME) announced that it is focusing its pipeline on a set of high value programs, each targeting a disease with well-understood bio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/prime-medicine-unveils-strategically-focused-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/prime-medicine-unveils-strategically-focused-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PRME"],"gpt_icon":0},{"id":"2471803309","title":"Prime Medicine Inc: Will Focus on Development of Two Programs for Treatment of Chronic Granulomatous Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2471803309","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471803309?lang=en_us&edition=fundamental","pubTime":"2024-09-30 19:02","pubTimestamp":1727694131,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nFWN3LC0V9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.primemedicine.com","stockEarnings":[{"period":"1week","weight":0.0074},{"period":"1month","weight":0.1233},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.2692},{"period":"1year","weight":-0.5066},{"period":"ytd","weight":-0.5372}],"compareEarnings":[{"period":"1week","weight":0.019},{"period":"1month","weight":0.0409},{"period":"3month","weight":0.1138},{"period":"6month","weight":0.1348},{"period":"1year","weight":0.3527},{"period":"ytd","weight":0.2435}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.013349},{"month":2,"riseRate":0.75,"avgChangeRate":-0.006023},{"month":3,"riseRate":0.75,"avgChangeRate":0.02763},{"month":4,"riseRate":0.5,"avgChangeRate":0.010576},{"month":5,"riseRate":1,"avgChangeRate":0.002703},{"month":6,"riseRate":0.5,"avgChangeRate":0.004716},{"month":7,"riseRate":0.75,"avgChangeRate":0.014069},{"month":8,"riseRate":0.25,"avgChangeRate":0.010977},{"month":9,"riseRate":0,"avgChangeRate":-0.015899},{"month":10,"riseRate":0.25,"avgChangeRate":-0.030391},{"month":11,"riseRate":0.666667,"avgChangeRate":0.001019},{"month":12,"riseRate":0.5,"avgChangeRate":-0.025302}],"exchange":"NASDAQ","name":"Prime Medicine, Inc.","nameEN":"Prime Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Prime Medicine, Inc.,PRME,Prime Medicine, Inc.股票,Prime Medicine, Inc.股票老虎,Prime Medicine, Inc.股票老虎国际,Prime Medicine, Inc.行情,Prime Medicine, Inc.股票行情,Prime Medicine, Inc.股价,Prime Medicine, Inc.股市,Prime Medicine, Inc.股票价格,Prime Medicine, Inc.股票交易,Prime Medicine, Inc.股票购买,Prime Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}